Facebook Instagram Pinterest Reddit Tumblr X Youtube
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 235

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Quarterly Psychedelics Briefing: Q3 2026

Weekly Psychedelic Policy Briefing, September 21, 2026

Health Canada Authorizes Optimi’s Natural Psilocybin Trial as House Bill Targets Botanical Drug Exclusivity

Pα+ Psychedelic Bulletin #232: Q2’26 Psychedelic Lobbying Update; DEA Again Moves to Schedule 5 Tryptamines; Oregon Backpedals Psilocybin Fee Hike

Podcast: Psychedelics in D.C., FDA’s Framework, and New Zealand’s MDMA Prescribers

Silo Pharma Enters into Sponsored Research Agreement with Columbia University to...

Nova Mentis Earns Psilocybin Orphan Drug Designation in Europe for Fragile...

MINDCURE Announces Financial Results for the First Quarter of Fiscal 2022

MYND Life Sciences Signs Agreement to Acquire Rights for the Use...

Entheon Biomedical Provides Corporate Update on Studies and Clinical Trials

Cybin Announces FDA Investigational New Drug Authorization of Cybin’s Sponsored Feasibility...

PT268 – Hamilton Morris – PCP, 5-MeO-DMT, and The Synthesis of...

MindMed Expands its Drug Development Pipeline with Launch of R(-)-MDMA Program

HAVN Life Announces Departure of Rick Brar as Director

Delix Therapeutics Announces Appointment of Dr. John Krystal to Scientific &...

Load more

EDITOR PICKS

Quarterly Psychedelics Briefing: Q3 2026

Weekly Psychedelic Policy Briefing, September 21, 2026

Health Canada Authorizes Optimi’s Natural Psilocybin Trial as House Bill Targets...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    Facebook Instagram Pinterest Reddit Tumblr X Youtube
    ©